Trastuzumab emtansine (T-DM1) is a novel therapeutic for HER2+ breast cancer patients with residual disease after neoadjuvant chemotherapy. Concurrent radiotherapy (RT) is offered to a subset of patients based on results from the KATHERINE trial which showed a favorable safety profile. With emerging therapies that necessitate concurrent RT, we must closely follow rates of skin toxicity. Our first 35 patients who underwent concurrent T-DM1 treatment with breast/chest wall (CW) ± nodal irradiation are reported. Most patients (22/35) had grade 2+ toxicity and 3 patients had grade 3 toxicities. We add our experience with radiation dermatitis and concurrent T-DM1 to contribute to existing reports.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982262 | PMC |
| http://dx.doi.org/10.1016/j.breast.2022.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy.
Curr Oncol
October 2023
Division of Oncology and Radiotherapy, University Hospital for Tumours, Sestre Milosrdnice University Hospital Centre, Ilica 197, 10000 Zagreb, Croatia.
Anti HER2 therapy and left breast adjuvant radiation therapy (RT) can both result in cardiotoxicity. The aim of this study was to evaluate the influence of radiation dose on cardiac structures on the values of the early cardiotoxicity marker high-sensitivity cardiac troponin I (hscTnI) in patients with HER2-positive left breast cancer undergoing adjuvant concomitant antiHER2 therapy and radiotherapy, and to establish a correlation between the hscTnI values and cardiac radiation doses. Sixty-one patients underwent left breast hypofractionated radiotherapy in parallel with anti-HER2 therapy: trastuzumab, combined trastuzumab-pertuzumab or trastuzumab emtansine (T-DM1).
View Article and Find Full Text PDFSafety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
Radiother Oncol
September 2023
Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. Electronic address:
Article Synopsis
- Recent advancements in breast cancer treatment, including the antibody drug conjugate trastuzumab emtansine (T-DM1), necessitate a comprehensive evaluation of its safety when combined with radiation therapy (RT).
- This study conducted a systematic review and meta-analysis, including nine articles that provided data on the safety of using T-DM1 alongside RT, revealing a notably high incidence of grade 3+ radionecrosis (17%).
- While the combination shows an acceptable safety profile for treating non-metastatic breast cancer, caution is needed for intracranial radiation, highlighting the need for international guidelines on the subject.
[Radiotherapy and targeted therapy for the management of breast cancer: A review].
Cancer Radiother
September 2023
Département de radiothérapie oncologique, institut Curie, université PSL, Paris, France.
The purpose of this study was to review the current knowledge regarding combinations of the most commonly used targeted therapies or those under development for the management of breast cancer with radiation therapy. Several studies have shown that the combination of radiation therapy and tamoxifen increased the risk of radiation-induced lung toxicity; therefore, the two modalities are generally not given concurrently. The combination of HER2 inhibitors (trastuzumab, pertuzumab) and radiation therapy appeared to be safe.
View Article and Find Full Text PDFDo statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort.
Medicine (Baltimore)
May 2023
Hacettepe University Medical School, Department of Medical Oncology, Ankara, Turkey.
Human epidermal growth factor receptor 2 (HER2)-targeting therapies have become crucial in the management of HER2-positive breast cancer. Trastuzumab emtansine (T-DM1) is a microtubule inhibitor and HER2-targeted antibody conjugate. T-DM1 resistance is most likely influenced by factors involved in the biological mechanisms of T-DM1 action.
View Article and Find Full Text PDFAcute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients.
Breast
February 2023
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
Trastuzumab emtansine (T-DM1) is a novel therapeutic for HER2+ breast cancer patients with residual disease after neoadjuvant chemotherapy. Concurrent radiotherapy (RT) is offered to a subset of patients based on results from the KATHERINE trial which showed a favorable safety profile. With emerging therapies that necessitate concurrent RT, we must closely follow rates of skin toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!